That was a thought, but given that yesterday was a public holiday for Victoria, perhaps all details not finalised.
I had a thought that perhaps IHL might licence all of Brainpark's ongoing work through relationship with Dr Paul which could be interesting, but would much rather something that pushes the current programs forwards.
Other could be FDA clearance recieved for IND to commence the extended Phase2 in the US, but I did think that this safety report would actually form part of that application so it might still a month or more away.
IHL Price at posting:
14.5¢ Sentiment: Buy Disclosure: Held
